Evidence map›Paper›PMID 41771573›Full record

ArticleCancer genomics & proteomics

NPM1 Drives ERK1/2-dependent Tumor Progression in Lung Cancer.

Hong-Beum Kim, Hee-Jeong Lee, Sang-Gon Park

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hong-Beum KimDepartment of Premedical Course, Chosun University School of Medicine, Gwangju, Republic of Korea.
Hee-Jeong LeeDepartment of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea.
Sang-Gon ParkDepartment of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea sgpark@chosun.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimLung cancer is the most lethal malignancy worldwide, and there remains an urgent need for reliable biomarkers to improve diagnosis and treatment. Nucleophosmin 1 (NPM1), a nucleolar phosphoprotein, has been implicated in hematological cancers, but its significance in lung cancer is less clear. This study investigated the oncogenic role of NPM1 in lung cancer and its involvement in ERK1/2 pathway activation in lung cancer cells. MATERIALS AND

methodsTranscriptomic data from TCGA were analyzed to assess NPM1 expression in lung cancer and normal tissues.

resultsNPM1 expression was significantly elevated in lung cancer tissues compared with normal samples. Silencing NPM1 reduced proliferation, colony formation, and tumor growth. Mechanistic studies revealed that NPM1 knockdown decreased phosphorylation of ERK1/2, indicating its role in activating this pathway.

conclusionNPM1 contributes to lung cancer progression

Indexed as

Lung NeoplasmsMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nuclear ProteinsAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudeNucleophosminBiomarkers, TumorMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NPM1 protein, humanNpm1 protein, mouseNuclear ProteinsNucleophosmindiagnostic biomarkerERK1/2 signalinglung cancerNucleophosmin 1 (NPM1)oncogene

Identifiers

PMID41771573
PMCPMC12951369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.